Data powered by Alphabet Inc.
Alembic
ALEMBICLTD
₹ 158.09
₹ 5.00
3.26%
Alembic Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | 2.05% | 33,97,184 |
| Weekly | 13.28% | 51,64,453 |
| Monthly | 44.82% | 5,33,99,177 |
Alembic Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| ALEMBICLTD | 2.05% | 13.28% | 44.82% |
| Index | - | - | - |
| Peer Avg. | 1.75% | 5.42% | 11.19% |
*Avg of index constituents
Alembic Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| ALEMBICLTD | 15.02 | 1.29 | 20.46 | 6.45 | 7.35 | 2.53 |
| Index | 36.20 | 6.77 | 17.25 | 17.89 | 19.69 | 1.20 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
*Avg of index constituents
Alembic Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 5.74% | 532.06% | 6.45% | 7.35% |
| FY '20-21 | -1.22% | -85.42% | 1.39% | 1.75% |
| FY '19-20 | -40.39% | 127.02% | 13.99% | 14.05% |
Alembic Shareholding Pattern
Promoters : 70.88%
FII : 1.12%
DII : 4.69%
Public : 23.31%
Others : 0%
Alembic Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 77.10 | 63.67 | 102.56 | 85.95 |
| FY '20-21 | 72.91 | 62.65 | 21.02 | 13.60 |
| FY '19-20 | 73.81 | 70.45 | 96.93 | 93.29 |
All values are in crores
Alembic Peer Comparison
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| ALEMBICLTD | 77.10 | 63.67 | 102.56 | 85.95 |
| MAYURUNIQ | 643.71 | 524.16 | 140 | 89.35 |
| GOKULAGRO | 10,304.09 | 10,093.68 | 226.88 | 112.94 |
All values are in crores
Alembic Share Price
Alembic Limited is an Indian company that develops, manufactures and markets pharmaceutical products such as dosage forms and active ingredients. The company operates through one segment, Pharmaceuticals. The Pharmaceutical segment manufactures and markets fermentation and chemical-based active ingredients (API). The company also conducts R&D in Vadodara. The company manufactures/provides three main products/services: Azithromycin, Venlafaxine and Telmisartan.